Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
C-Max (Cerebrolysin variant) vs P21
An educational, source-based comparison of C-Max (Cerebrolysin variant) and P21 — how each peptide works, what it's researched for, and what to know before going deeper.
Concentrated neuropeptide fraction for cognitive support research.
A concentrated fraction of cerebrolysin containing specific neuropeptide sequences. Research suggests enhanced delivery of neurotrophic factors supporting synaptic maintenance and neurogenesis.
- Post-stroke cognitive recovery
- Vascular cognitive impairment
- Traumatic brain injury rehabilitation
- • Not FDA-approved in the US; approved in select countries.
- • Requires medical supervision for IV administration.
A synthetic peptide derived from cerebrolysin. Research suggests it promotes synaptic plasticity by enhancing BDNF expression and inhibiting prolyl endopeptidase, an enzyme involved in neurodegenerative processes.
- Synaptic plasticity and memory
- Neuroprotection in Alzheimer's models
- Cognitive recovery after brain injury
- • Experimental; limited human data available.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| C-Max (Cerebrolysin variant) | Concentrated neuropeptide fractions in stroke rehabilitation | Neurorehabilitation and Neural Repair | 2018 | Improved functional outcomes in post-stroke patients receiving neuropeptide therapy. |
| P21 | P21 promotes synaptic plasticity in aged rodents | Neuroscience Letters | 2015 | Enhanced dendritic spine density and BDNF expression in hippocampal tissue. |
Side-effect & safety grid
- Not FDA-approved in the US; approved in select countries.
- Requires medical supervision for IV administration.
- Experimental; limited human data available.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
C-Max (Cerebrolysin variant) vs P21 — Key differences
- Class: C-Max (Cerebrolysin variant) is classified as Nootropic · Neurotrophic, while P21 is Nootropic · Neuroprotection.
- Primary research focus: C-Max (Cerebrolysin variant) — post-stroke cognitive recovery; P21 — synaptic plasticity and memory.
- Tag: Cognition vs Cognition · Neuroprotection.